Podcasts about Interventional neuroradiology

Dr. Hoffman continues his conversation with Dr. Kieran Murphy, author of “The Essence of Invention: Medicine and the Joy of Creativity,”

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman interviews Professor Kieran Murphy, an interventional neuro radiologist and prolific inventor from Toronto Western Hospital. Dr. Murphy has developed numerous innovative medical devices and filed 60 patents. He shares insights from his book, “The Essence of Invention: Medicine and the Joy of Creativity,” discussing his work on medical innovation, his unique background, and personal experiences that have driven his creative solutions. The conversation covers various topics, including the importance of creativity, the impact of bureaucracy on modern medicine, and groundbreaking innovations like ozone therapy for herniated discs and a radio-protective supplement for medical personnel. Dr. Murphy emphasizes mindfulness and paying attention to phenomena as key components for fostering creativity and innovation in medicine.

Watch this episode on YouTube hereInterventional Neuroradiology (also sometimes referred to as "endovascular neurosurgery and "interventional neurology") is a relatively young field, yet it has achieved remarkable progress since its inception. Our guest is Dr. Pascal Mosimann, our interventional neuroradiologist and Division Head, Interventional and Diagnostic Neuroradiology at University Health Network. In this episode of Radiologists we talk about what interventional neuroradiology is, why Canada is a great place to become a specialist in this field, the challenges this specialty faces today and its bright future as well as the incredible opportunities it holds, how one can become an interventional neuroradiologist and who is best suited for this field, and, as always, so much more!The content provided in this episode is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions you may have regarding a medical condition.Produced by Inna LevchukThanks for listening! Watch Radiologists on YouTube hereFollow us on: XInstagramLinkedInVisit our website: imagingtoronto.com

One minute, you and a friend are talking about your weekend plans. And the next thing you know, you feel confused, have trouble speaking and start slurring words. That's what having a stroke feels like. If treated “fast” – and we'll get to what the acronym F.A.S.T. means - a stroke can be reversed and permanent disability prevented or minimized.  The longer the stroke lasts, the more brain damage occurs. The faster you treat it, the more brain you protect. F.A.S.T. represents the top signs of a stroke: F – Face Drooping; A – Arm Weakness; S – Speech Difficulty; and T – Time to call 9-1-1.  Host: David Jeannot Guests: Guilherme Dabus, M.D., Co-Director of Interventional Neuroradiology at Baptist Health Miami Neuroscience Institute Meisha McIntosh, Stroke Survivor

How can we minimize the invasiveness of implantable brain-computer interfaces? What are the secrets behind using interventional neuroradiology approaches to create technology for brain interfacing? And what does it truly mean to innovate in the realm of healthcare? Welcome, dear listeners, to another exciting episode of the "Neurocareers: Doing the Impossible!" entrepreneurial podcast series! Today, we embark on a journey into the cutting-edge world of neurotechnology and innovation. Our focus? The incredible advancements in minimally invasive brain interfaces led by a pioneer in the field, Dr. Jose Morales. Dr. Morales, a co-founder of Vonova and an accomplished Neurointerventional Surgeon, combines his deep passion for neuroscience with a remarkable flair for innovation. With a background steeped in translational neuroscience and experience in molecular-scale research, Dr. Morales is pushing the boundaries of neurointervention. His mission? To revolutionize diagnostic and therapeutic approaches for various neurological conditions while minimizing the invasiveness of traditional neurosurgery. But Dr. Morales isn't just a visionary; he's a recognized leader in his field. His accolades include winning the UCLA Health Innovation Challenge and Radiological Sciences Exploratory Research seed grants, as well as being selected as a finalist for the inaugural MedTech Color competition and CLS FAST program in 2021. A co-founder of the neurotechnology company, Vonova, Inc., he and his team have been selected as an NIH Blueprint MedTach Seedling and EvoNexus Incubator portfolio company, as well as a UCLA Anderson Venture Accelerator company in 2023. At the forefront of Vonova lies the development of minimally invasive brain interfaces. The goal? To transform the treatment of drug-resistant epilepsy and other neurological disorders. Through the ingenious use of catheter-based technology, Vonova aims to provide solutions that are both less invasive and more effective for patients. In this episode, we'll delve into Dr. Morales's extraordinary journey, exploring his career as a Neurointerventional Surgeon, his deep-rooted passion for neuroscience, and the groundbreaking work unfolding at Vonova. Together, we'll uncover the challenges and opportunities in this dynamic field, shining a spotlight on the thrilling intersection of medicine and technology. Prepare to be inspired and enlightened as we engage in this captivating conversation with Dr. Jose Morales, a visionary shaping the future of neuroendovascular theranostics. Tune in to 'Neurocareers' and join us for this enlightening exploration of the boundless potential within the world of neuroscience and innovation. About the Podcast Guest: José Morales is an entrepreneur and a neurointerventional surgeon at Pacific Neuroscience Institute (Santa Monica, CA). He completed his Neurology Residency at the Ken and Ruth Davee Department of Neurology at Northwestern University and Vascular Neurology and Interventional Neuroradiology Fellowships at the University of California Los Angeles. He is a medical school graduate from the University of Chicago Pritzker School of Medicine, where he served as the President of the American Academy of Neurology (AAN) Student Interest Group in Neurology and participated in an extended curriculum program under the Scholarship and Discovery track to conduct research in Computational Neuroscience and Brain Machine Interface, which was funded by the AAN Medical Student Research Scholarship. Prior to enrolling in medical school, Dr. Morales investigated the neuroanatomical correlates of critical period plasticity in the dorsal lateral geniculate nucleus at Harvard Medical School. He is also a graduate of Imperial College London, where he completed a Master of Science in Integrative Neuroscience and investigated the functional connectivity of memory and language networks associated with normative and pathological aging in humans for his graduate thesis in the Computational, Cognitive, and Clinical Neuroimaging Laboratory. Dr. Morales is a clinician-scientist, who has published in journals, such as Neuron, Nature, and Stroke, and a medical device innovator with several issued medical device patents. For his innovative concepts, Dr. Morales was selected as a fellow for the 2021-2022 UCLA Biodesign Accelerator program. Learn about Vonova here: https://www.vonova.io/  Get in touch with Jose Morales, MD, via LinkedIn: http://linkedin.com/in/jose-m-9672344b About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume and cover letter development, and interview preparation Access to a network of professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news

In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, speaks with Dr. Marco Colasurdo (1) and Prof. Dheeraj Gandhi (2), authors of the original research article, "Predictors for large vessel recanalization before stroke thrombectomy: the HALT score" - https://jnis.bmj.com/content/early/2023/04/25/jnis-2023-020220 This paper is free-to-access for a month following the publication of this podcast.  Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767  Thank you for listening! This episode was edited by Brian O'Toole.  (1) Interventional Neuroradiology, Dept. of Diagnostic Radiology, Uni. of Maryland Medical Center, Baltimore, Maryland, USA  (2) Dept. of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA

In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, speaks with Dr. Marco Colasurdo (1) and Prof. Dheeraj Gandhi (2), authors of the original research article, "Predictors for large vessel recanalization before stroke thrombectomy: the HALT score" - https://jnis.bmj.com/content/early/2023/04/25/jnis-2023-020220 This paper is free-to-access for a month following the publication of this podcast. Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767 Thank you for listening! This episode was edited by Brian O'Toole. (1) Interventional Neuroradiology, Dept. of Diagnostic Radiology, Uni. of Maryland Medical Center, Baltimore, Maryland, USA (2) Dept. of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA

Host Professor Majda Thurnher is joined by Prof. Naci Kocer, Professor of Radiology at Istanbul University, Cerrahpasa School of Medicine. Prof. Naci Kocer has been responsible for interventional neuroradiology and diagnostic neuroradiology at the very same institution since 1993. He is also the author of Giant Intracranial Aneurysms: A Case based Atlas of Imaging and Treatment.And also Prof. Isil Saatci. A Professor of Neuroradiology in the Radiology Department of Yuksek Ihtisas University, Koru Hospital, Turkey. Together they discuss who inspired them and their first intervention's. The hot topics in intervention neuroradiology now. The ESNR's annual meeting in Vienna and which professional topics will be discussed............Our podcast is your reference for education and updates from the European Societyof Neuroradiology (ESNR). Join expert moderators and guests in reviewing,discussing, and debating various topics within all fields of diagnostic andinterventional neuroradiology. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Neurocareers, the podcast that proves the impossible is possible! We're thrilled to bring you the second episode of our BCI Award Neurocareers series featuring Prof. Nicholas Opie, the mastermind behind the revolutionary Stentrode and endovascular neural interfaces. Prof. Opie, a biomedical engineer and the founding CTO of Synchron, knows what it takes to succeed in the innovative field of neurotech. Prof. Opie's Stentrode project won 1st place in the International BCI Award competition in 2021. In this podcast episode, he'll share his top tips for winning the International BCI Award and building a successful career in the industry. Join us as we dive deep into the Stentrode revolution and discover how endovascular neural interfaces are changing the game. Prof. Opie will take us through his groundbreaking research and share insights on making the impossible possible in neurotech. As always, Neurocareers inspires and educates you on the exciting and ever-evolving world of neuroscience and neurotechnologies. Don't miss this opportunity to learn from one of the best in the field! This BCI Award Neurocareers series is a partnership between Milena Korostenskaja, PhD at the Institute of Neuroapproaches, and Christoph Guger, PhD at g.tec biomedical engineering. About the Podcast Guest: Professor Nicholas Opie, BE BSc PhD MBA, is a leading biomedical engineer and an expert in neural interfaces. He currently serves as the Laboratory Head of the Vascular Bionics Laboratory in the Department of Medicine at the University of Melbourne, where he is also an NHMRC Research Fellow. Throughout his career, Prof Opie has brought multiple biomedical devices from concept to clinic, including a suprachoroidal retinal prosthesis (bionic eye) that aims to restore vision to individuals with profound vision loss, and a motor neuron prosthesis (bionic spine) that seeks to restore independence, communication, and mobility to individuals with paralysis. He has published over 55 peer-reviewed journal articles, including in Nature Biomedical Engineering and Nature Biotechnology. Additionally, he has filed over 90 patents and was awarded the 2021 NFMRI John Raftos AM Award for Advancing Innovation. Prof Opie is also Synchron's founding Chief Technology Officer (CTO), a neural interface company based in Melbourne and New York. He has raised over AUD$210M in private funding and grants and designed Synchron's flagship product, the Stentrode™. The Stentrode is listed in Time Magazine's Top 100 Inventions of 2021 and aims to provide treatment for debilitating medical illnesses while empowering patients by reconnecting them online in ways that dramatically improve their lives. Following a successful first-in-human trial conducted in Australia on the Stentrode motor neuroprosthesis, Prof Opie and Synchron recently received approval from the US FDA. This approval paves the way for a trial in the US, which will commence this year and represents a significant step towards the first FDA approval for implantable brain-computer interfaces. To learn more about Prof Opie and his work, visit his profile page at the University of Melbourne: https://findanexpert.unimelb.edu.au/profile/430403-nicholas-opie. You can also check out the Stentrode SWITCH study, which involved four patients: https://pubmed.ncbi.nlm.nih.gov/36622685/. Learn more about Synchron's innovative technology on their website: https://synchron.com/. Finally, connect with Prof Nicholas Opie on LinkedIn: https://www.linkedin.com/in/professor-nicholas-opie-4603289a/. About the podcast host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume and cover letter development, and interview preparation Access to a network of professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

 Dr. Steven Hetts is Chief of Interventional Neuroradiology at the UCSF Mission Bay Hospitals.  He founded the  Interventional Neuroradiology services at San Francisco General Hospital. Dr. Hetts describes how to create better outcomes after having a stroke and the importance of immediate medical attention.I invite you to listen!If you feel this Podcast is beneficial, I encourage you to share it, and I invite you to leave a 5-Star Review. It does so much for putting this podcast in the hands of those that may need it.Connect with me!Website:  In the Rising Podcast WebsiteEmail:  Bettina@intherising.comPinterest: Facebook

World Stroke Day is an opportunity to raise awareness of the serious nature and high rates of stroke and talk about ways in which we can reduce the burden of stroke through better public awareness of the risk factors and signs of stroke. It is also an opportunity to advocate for action by decision-makers at global, regional, and national levels that are essential to improve stroke prevention, access to acute treatment and support for survivors and caregivers. GET AHEAD OF STROKE was founded in 2016 by the Society of NeuroInterventional Surgery (SNIS), today the campaign is supported by a coalition of organizations with the goal of securing the best possible outcomes for stroke patients by driving policy change and public awareness nationwide. Every 40 seconds…someone in the U.S. has a stroke. GET AHEAD OF STROKE is a national public education and advocacy campaign designed to improve systems of care for stroke patients. About Dr. Steven Hetts Steven Hetts, MD is Chief of Interventional Neuroradiology at the UCSF Mission Bay Hospitals, where he provides cutting-edge, minimally invasive endovascular therapy for children and adults with stroke, cerebrovascular disease and tumors, including retinoblastoma. He founded the Interventional Neuroradiology services at San Francisco General Hospital and the San Francisco Veteran's Administration Hospital, where he served as Chief until 2015. Throughout his career, Dr. Hetts has maintained an active clinical practice at UCSF Parnassus, treating patients with stroke, brain aneurysms, arteriovenous malformations, dural arteriovenous fistulas, spinal vascular malformations, and tumors including meningioma. --- Send in a voice message: https://anchor.fm/tntbsmedia/message

Lisa is joined by Steven Hetts, MD to talk about Strokes for World Stroke Day on October 29th.Steven Hetts, MD is Chief of Interventional Neuroradiology at the UCSF Mission Bay Hospitals, where he provides cutting-edge, minimally invasive endovascular therapy for children and adults with stroke, cerebrovascular disease and tumors, including retinoblastoma. He founded the Interventional Neuroradiology services at San Francisco General Hospital and the San Francisco Veteran's Administration Hospital, where he served as Chief until 2015. Throughout his career, Dr. Hetts has maintained an active clinical practice at UCSF Parnassus, treating patients with stroke, brain aneurysms, arteriovenous malformations, dural arteriovenous fistulas, spinal vascular malformations, and tumors including meningioma. Dr. Hetts is also the founding Co-Director of the UCSF Hereditary Hemorrhagic Telangiectasia Center of Excellence wherein he and his colleagues provide care for patients with vascular malformations of the brain, severe nosebleeds (epistaxis), and arteriovenous malformations of the lung and other organs. Dr. Hetts received his MD from Harvard Medical School and his undergraduate degree from Harvard College. He completed his medical internship at Stanford and his diagnostic radiology residency, diagnostic neuroradiology fellowship, and interventional neuroradiology fellowship at UCSF, where he joined the faculty in 2008.A patient's access to appropriate care in a timely manner can make a huge difference in his or her outcomes. According to a 2017 study by the American Academy of Neurology, severe stroke patients gain a week of healthy life for every minute that is saved in getting them to appropriate care.Stroke costs in the U.S. are currently estimated at about $46 billion. The minimally invasive nature of thrombectomy helps stroke patients get back on their feet so they are able to live independently and work again.Nearly 2 million brain cells die every minute a stroke goes untreated. For the best possible outcome, a stroke patient ideally needs to receive a thrombectomy within 24 hours.Patients who need emergency care deserve the best care possible, whether it is for trauma or stroke.Thousands of lives could be saved every year in the state, but that will only happen if people pick up the phone and call 911. People need to know how to act FAST, so they can help themselves or their loved ones survive stroke. FAST- Facial drooping, Arm weakness, Speech difficulties, Time to call EMS.Like trauma, stroke is time-sensitive and requires first responders to determine stroke severity. Unlike trauma, most states do not have requirements for first responders to take severe stroke patients to a facility specially equipped to treat them. Do stroke patients deserve less than trauma patients?Every 40 seconds, someone in the U.S. has a stroke. Nearly 20% — 140,000 annually — die from their condition, and many more are left permanently disabled. Physicians from the Society of NeuroInterventional Surgery (SNIS), the sponsoring organization for the GAOS coalition, say that if the nation's stroke system of care looked more like our trauma triage system, patients would experience less disability, and more would survive.  Sign up for our email list at GetAheadofStroke.org and search hashtag #SurviveStroke or #StrokeAwarenessMonth on social media to learn how the campaign is helping to improve stroke care across the country. Currently, most states do not have clear protocols to ensure a person who is having a severe stroke is transported directly to a Level 1 stroke center, where they would have access to a specially trained neuroendovascular care team that can help them 24/7/365.

Do you have the nerve to stick the needle into the artery and have the blood shooting back at you? Are you capable of making life and death decisions? Then a career as an Interventional Neuroradiologist might be the right fit for you! Even if you have already found your dream job – you will be blown away to learn how Interventional Neuroradiologists are saving the lives of people with acute strokes and other severe acute neurological conditions! Meet and greet Kristine Blackham, MD, from the University Hospital of Basel, Basel, Switzerland, who shares one of the most challenging clinical cases in her career and provides an eye-opening clinical and research practice comparison between Switzerland and the US. In addition, Dr. Blackham shares her story of the profound impact life coaching had on her life and its potential to transform the lives of specialists working in stressful clinical settings. Tune in and learn what the future of treating neurological conditions holds! Enjoy this informative podcast with Dr. Blackham, and stay tuned!   Find more about Dr. Blackham's clinical research here: https://www.researchgate.net/profile/Kristine-Blackham Learn about Dr. Blackham's offered coaching here: https://kblackhammd.com/ Get in touch with Dr. Blackham by contacting her via email: kristine.blackham@gmail.com The podcast is brought to you by The Institute of Neuroapproaches and its founder - Milena Korostenskaja, PhD - a neuroscience educator, neuroscience research consultant, and career coach for people in neuroscience and neurotechnologies: https://www.neuroapproaches.org/ Get in touch with Dr. K. at neuroapproaches@gmail.com or schedule a free coaching consultation at https://neuroapproaches.as.me/

Prof. Alexander Radbruch, Chair Diagnostic and Interventional Neuroradiology, University of Bonn - Join our session with Prof Alexander Radbruch, head of the newly created Clinic for Neuroradiology at the University Hospital Bonn. As one of Europe's most influential researchers in radiology, he integrates digitalisation and artificial intelligence to improve oncological diagnostics.

What do you do when your high school aptitude test suggests a career as a short-order cook or airplane pilot? You go on to earn your medical degree from the University of Missouri‐Kansas City 6 year BA/MD program, complete your radiology residency at St. Francis Medical Center and the University of Pittsburgh, and finish fellowships in Diagnostic Radiology and then Interventional Neuroradiology at Stanford University. From there you join the faculty at the Massachusetts General Hospital, the Brigham and Women's Hospital, and become Chair and Professor of Radiology at Boston University School of Medicine before taking on your current role as Chair and Professor of Radiology at the University of California, San Diego, (UCSD) in the School of Medicine.

On Episode 1 of the Stroke Alert podcast, host Dr. Negar Asdaghi highlights two featured articles from the February 2021 issue of Stroke. This episode also features a conversation with Drs. Fabian Flottmann and Matthew Maros from the Department of Diagnostic and Interventional Neuroradiology, University Medical Center, in Hamburg, Germany, to discuss their article “Good Clinical Outcome Decreases With Number of Retrieval Attempts in Stroke Thrombectomy: Beyond the First-Pass Effect.” Dr. Negar Asdaghi:          Are women more likely to suffer from stroke than men? Are oral anticoagulants safe in atrial fibrillation patients with a prior history of GI bleeding? Does pregnancy increase the risk of intracerebral hemorrhage in patients with cavernous malformation? Does the number of retrieval attempts during thrombectomy affect the outcomes of stroke patients in whom successful reperfusion is achieved? In today's podcast, we address some of these topics and much more. You're listening to the Stroke Alert Podcast. Stay with us. Dr. Negar Asdaghi:         From the Editorial Board of Stroke, welcome to the Stroke Alert Podcast. My name is Negar Asdaghi. I'm an Associate Professor of Neurology at the University of Miami, Miller School of Medicine, and the host of the monthly Stroke Alert Podcast. We're starting our podcasts with the February 2021 issue of the journal, which also features a special section on Go Red for Women stroke, a comprehensive American Heart Association platform to improve the vascular health of women globally. I hope you enjoy it. Dr. Negar Asdaghi:         Cavernous malformations or cavernomas are angiographically called vascular abnormalities, which can pose an increased risk for intracerebral hemorrhage. Cavernomas can have diverse neurological presentations ranging from mild neurological symptoms to seizures, but in some cases may remain entirely asymptomatic and are diagnosed incidentally as part of routine neuroimaging completed for other reasons. Earlier studies had reported higher rates of intracerebral hemorrhage from cavernomas during pregnancy, and have postulated a hormone-related increased expression of vascular endothelial growth factor or basic fibroblasts growth factors to explain this increased rate. Subsequent studies, however, have failed to demonstrate either progesterone or estrogen receptors in cavernomas. So the question is, should presence of cavernous malformation, whether symptomatic or asymptomatic, influence the reproductive choices of women of childbearing age? In the “Influence of Pregnancy on Hemorrhage Risk in Women With Cerebral and Spinal Cavernous Malformations,” Dr. Nycole Joseph and colleagues from the Departments of Neurology and Neurosurgery from Mayo Clinic Rochester in Minnesota evaluated 365 pregnancies and 160 women with brain or spinal cord cavernomas. They found that during the cumulative 402 years of study follow-up, the risk of hemorrhage amongst non-pregnant patients in the study was 10.4% per year. They found only four patients with clinical hemorrhage during pregnancy, all of which resulted in the cavernomas being first diagnosed. None of the hemorrhages occurred during delivery, and all of the four patients had functionally independent outcomes by three months. Importantly, they found that no patient who became pregnant after the diagnosis of cavernous malformation had a hemorrhage while pregnant. They had a total of 33 pregnancies in the study, including one patient who had previously bled during a prior pregnancy and also patients with brainstem lesions and those who presented with hemorrhage at diagnosis. Both of these are factors for hemorrhage in cavernomas. So, in summary, in this prospective study, pregnancy did not increase the risk of hemorrhage in women with a known brain or spinal cord cavernous malformation. And the vaginal delivery was safe in this population. The authors concluded that the presence of cavernous malformation should not influence the reproductive choices in women or their type of delivery. Now, speaking of hemorrhage risk, let's move on to our next paper on anticoagulation therapy in patients with atrial fibrillation. The decision to start anticoagulants for atrial fibrillation can often be challenging in those who have suffered from a prior gastrointestinal bleeding. Prior studies have shown that the non–vitamin K antagonist oral anticoagulants, or NOACs, can carry a comparable and, in some cases, even a higher risk of GI bleed than warfarin. It should be noted that patients with a prior GI bleed were generally excluded from the pivotal randomized control trials that approved NOACs. And importantly, the risk of bleeding may also be higher in certain race/ethnic groups, such as the Asian population. In the article titled “Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding,” Dr. Soonil Kwon from the Department of Internal Medicine, Seoul National University Hospital, in Seoul, Republic of Korea, studied over 42,000 anticoagulant–naïve patients with nonvalvular atrial fibrillation and prior GI bleed from 2010 to 2018 as part of a retrospective, observational cohort study in Korea. They evaluated the risk of ischemic stroke, major bleeding and combined outcomes in this population. What they found was that, not surprisingly, close to 60% of patients were initiated on a NOAC, with rivaroxaban leading dabigatran, apixaban, followed by edoxaban in terms of frequency of agents used. Just over 40% of patients were started on warfarin. Now, over the study follow-up, when they looked at the safety by looking at major bleeding rate and effectiveness by assessing ischemic stroke rates, NOACs generally did better as compared to warfarin, resulting in 39% risk reduction in recurrent stroke, 27% risk reduction in major bleeding and 34% risk reduction in composite outcomes as compared to warfarin. And the rates of upper and lower GI bleed were similar in NOACs versus warfarin users. NOACs still did better as compared to warfarin amongst patients who suffered from GI bleed as they had a lower transfusion rates and shorter hospital stay. NOACs were also associated with lower risks of fatal clinical outcomes except for fatal GI bleed. So the authors concluded that contrary to some of the prior reports, NOACs may be a better option than warfarin for stroke patients and atrial fibrillation patients with prior GI bleed. Dr. Negar Asdaghi:         Moving from secondary prevention to acute stroke therapy, our last article discusses how the technical details of endovascular thrombectomy may affect the outcomes in patients with ischemic stroke. So, achieving a successful reperfusion is the cornerstone of improving clinical outcomes in patients undergoing endovascular therapy, but how many retrieval attempts should be made by the interventionist to obtain that desired successful reperfusion is still unclear. Importantly, if successful reperfusion is ultimately achieved, it's still not clear if there's a relationship between the number of retrieval attempts and favorable clinical outcomes.  Joining me now are doctors Fabian Flottmann and Matthew Maros from the Department of Diagnostic and Interventional Neuroradiology, University Medical Center, in Hamburg, Germany, who are the first and senior authors of the study titled “Good Clinical Outcome Decreases With Number of Retrieval Attempts in Stroke Thrombectomy: Beyond the First-Pass Effect.” Good morning from Florida, and good afternoon, Fabian and Máté, in Germany. Thank you for joining us. Dr. Fabian Flottmann:    Thank you very much, Negar, for the nice introduction. Good afternoon from Hamburg. At the moment, it's really, really cold here. It's -4 degrees Celsius. I can't translate it to Fahrenheit, but it's pretty cold, let me assure you. And thank you very much for having us today. Dr. Negar Asdaghi:         It's great to have you. So I start with Fabian. This is a very interesting and timely study as we're learning more that the way in which we achieve a goal in acute stroke reperfusion therapies is almost as important as the goal itself. Can you tell us a bit about the background of your study, Fabian, and why you felt the need to look at these granular details, which unfold inside the angio suite during endovascular thrombectomy? Dr. Fabian Flottmann:    Of course, that's a question that's highly relevant for a neurointerventionalist. This research topic developed from our clinical practice, because quite often we have the situation in the angiography suite, where we try to open a vessel, a patient with a large vessel occlusion, and everything is very easy if the vessel opens after one retrieval attempt, because everybody is happy and you can end the procedure. But what happens if the vessel doesn't open? Then you try again. And what happens if the vessel doesn't open? You try it again, and so on and so on. So the question is, when should you stop? And we ask ourselves, are these maneuvers that we do, like three or four or five maneuvers, are they as successful or as beneficial for the patient as the first maneuver? We did an analysis of our data in Hamburg, and that led to the first paper that we published in Stroke in 2018. And our finding was that the third or fourth retrieval, they were successful in achieving recanalization, but the clinical outcome of those patients was not as good as those patients that you opened with just one retrieval attempt. That was the first finding that we had with our data and our center. And then in the same year, the first pass effect was described. The first pass effect, being the finding that the first retrieval attempt is the most important for the patient. This data was very interesting. And then there were other publications that said, no, there's no connection between the number of retrieval attempts and the clinical outcome. So, as always, in science, when there's more than one opinion, things begin to get interesting. And we said we want to investigate this further. And we decided to do a multicenter study with more patients. And we decided to look at each retrieval attempt separately, to not look just at a first retrieval attempt versus the others, but at each retrieval attempt. Dr. Negar Asdaghi:         So interesting indeed. Please tell us, before you tell us about the study findings, about the German Stroke Registry. How many years has the registry been active, and how many centers are involved, and please walk us through your study population and the selection process of your study? Dr. Fabian Flottmann:    Germans Stroke Registry. It's a systematic observational registry study from Germany. It's academic, it's independent, prospective, multi-central, there are 25 centers who participate in this registry. And its goal is to have a systematic evaluation of endovascular stroke treatment in Germany. There are stroke centers from all around the country who consecutively enroll their patients. All patients with an intention to treat in the angiography suite are included. All the patient data are collected at the center and all these data are then centralized and we have a central quality check. And what is important that we also try to include the clinical follow-up information for every patient at day 90. So, the modified Rankin Scale at day 90 is also included. And in our work, we did an analysis of the first 2,600 patients of this German Stroke Registry, and our goal was to eliminate bias. So, for example, we wanted to include data on the stroke severity, the NIHSS score, the amount of early infarction, the ASPECTS score and the location of occlusion, the age of the patient. We selected all the patients that had these data entered. So, we were able to select about 1,200 patients from the German Stroke Registry that fulfilled our inclusion criteria for the present study. To our knowledge, this is the largest multicentric, retrospective study that investigated this effect of retrieval attempts on clinical outcome. Dr. Negar Asdaghi:         This is really nice because we are really not used to getting granular details and radiographic details in such large numbers. So, the multicenter nature and the large number of patients included in your study are certainly important strengths of your paper, and that should be noted. Now, Matthew, over to you. Please tell us the main findings of the paper. Dr. Matthew Maros:     So, one specialty of our applied methodology is that we used a generalized mixed-effects models, if we didn't know logistic regression framework. That means that our target variable was the mRS90 and the good functional outcome, defined by zero to two scores by mRS. We also implied this framework to be comparable to the HERMES meta-analysis by Goyal et al. And we investigated, in our primary analysis, the effect of age, the baseline stroke severity NIHSS score, ASPECTS score, and also the main explanatory variable that we investigated was the successful reperfusion at N-th retrieval attempt. And we found that, so as one would expect, a younger age and the less severe stroke clinical manifestation, like NIHSS score, was inversely associated with a good functional outcome. So, younger patients and less severe stroke were associated with a favorable outcome. And also, a less severe ischemic changes on a non-contrast head CT, so ASPECTS score eight, nine or ten, were also independent predictors for a good function outcome at 90 days. Our main finding was that the success at the first, second, or third retrieval attempts were significantly and independently associated with a good functional outcome. And interestingly, the effect of the consecutive retrieval attempts were gradually diminishing from an odds ratio from six (around) to three. Dr. Negar Asdaghi:         This is interesting. So, basically, what you found is that you go in with the first attempt, second and third, you don't achieve that successful recanalization. If you achieve your successful reperfusion after the third attempt, it's good, but not so good, meaning that it doesn't translate to that beautiful, favorable outcome at 90 days as it did for the first three attempts. Dr. Matthew Maros:      So, for four or more retrieval attempts, this positive effect on the outcome has flattened, so the curve is more like a sigmoid curve that was asymptotic to a virtual threshold. Dr. Negar Asdaghi:         Understood. So, I find it very interesting that this decline in the odds of favorable outcome, despite successful reperfusion, was not simply a factor of time, meaning that, if you tried once and you achieve reperfusion right away, it's so much faster. And of course, time is brain, but if you try five times, it would take longer. It is interesting in your results and your multivariate analysis that even if you adjusted for the factor of delay in time, the results persisted. Could you please tell us about your multivariate analysis and what other factors and co-founders you adjusted for? Dr. Matthew Maros:      Exactly. So, as a sensitivity analysis, we also included the time from groin puncture to flow restoration and also sex, and also to be almost identical or highly similar to the model applied in the HERMES meta-analysis. We also included the site of the intracranial occlusion and better intravenous thrombolysis was administered or not. And in the sensitivity analysis, we had almost 90% of our dataset. So almost a thousand one hundred patients. And we found that all the effects of age and NIHSS score stayed significant, and also the effect of the first, second and third retrieval attempts associated with good functional outcome at 90 days were also significant. While interestingly, the effect of intravenous thrombolysis, and also the ASPECTS score, had diminished, but also just narrowly escaped a significant threshold. And interestingly, the effect of time, so time from groin puncture to flow restoration, seemed to be not relevant or be interpreted that way, that the number of retrieval attempts and the effect that we see is not a surrogate of time, that it simply takes longer to perform the interventions, but it's the true effect of achieving recanalization at a certain attempt. Dr. Negar Asdaghi:         So, what should be our takeaway from your study, Fabian? Is three that magic number? Are we asking the interventionalist to stop the procedure after the third retrieval attempt if they're unsuccessful, and what should the future hold in terms of studies on this project? Dr. Fabian Flottmann:    That's the most important question. Of course, we have to keep in mind that every patient and every intervention is different. The decision to continue or stop the thrombectomy procedure is a very important decision, which is taken by the neurointerventionalist together with his team. And they will take into account multiple factors, including patient's biography, medical history at time from symptom onset, image data, and so on. Our study can provide some guiding information when making this decision. And yes, three could indeed be called a magic number in the following sense. We would like to encourage interventionalists to make at least three attempts in case of persistent occlusion, because we can see a clear benefit even when reperfusion is achieved after the third attempt. Then, in patients with younger age and/or, for example, a good ASPECTS score, even more retrieval attempts are probably warranted regardless of IV thrombolysis, site of occlusion and potentially increased procedure time. Of course, in all these retrospective studies, a bias remains. We don't know why the procedure was stopped in each case. The best thing would be a randomized controlled trial with the following design. You could, in case of persistent occlusions, after two retrievals, randomize to continue or to stop the procedure. And then we would know what the right answer is. So, taken together, our study suggests that in EVT for anterior circulation strokes, at least three retrieval attempts should be performed in cases of persistent occlusion, and up to five attempts of beneficial association with good clinical outcome is expected. Dr. Negar Asdaghi:         Doctors Fabian Flottmann and Matthew Maros, thank you very much for joining us and congratulations on this work. And this concludes our podcast today. Don't forget to check the February table of contents for the full list of publications, including original contributions, brief reports, editorials, and our special section on Go Red for Women stroke. Until our next podcast, stay alert with Stroke Alert.

Dr. Ted Achacoso is the founding pioneer of the clinical practice of Health Optimization Medicine (HOMe), which is the detection and correction of imbalances at the level of the metabolome. He was mentored by the founding pioneer of Anti-Aging Medicine and Nutritional Medicine, Thierry Hertoghe (Dr. Ted is double board-certified, Paris), mentored by the founding pioneer of Medical Informatics and research scientist in Artificial Intelligence, William S. Yamamoto (Washington, DC), mentored by the founding pioneer of Socially Responsible Investing and Finance (now called Impact Investing), D. Wayne Silby (Washington, DC), and mentored by the country pioneers of Interventional Neuroradiology, Neurology, and Pharmacology/Toxicology (Manila).   He maintains tricontinental clinics and teaching in Health Optimization Medicine and Practice. He formulated one of the most sought after nootropics in the market today, Blue Cannatine.    Learn more at https://troscriptions.com/blue-cannatine/ (discount code "biohacks" to save). 

In this podcast, Felipe de Albuquerque talks to Istvan Szikora, Neurointerventions, National Institute of Clinical Neurosciences, Budapest, Hungary, about the official document of Standards for European training requirements in interventional neuroradiology guidelines by the Division of Neuroradiology/Section of Radiology European Union of Medical Specialists (UEMS), in cooperation with the Division of Interventional Radiology/UEMS, the European Society of Neuroradiology (ESNR), and the European Society of Minimally Invasive Neurological Therapy (ESMINT). Read the paper on the JNIS website: https://jnis.bmj.com/content/early/2019/11/15/neurintsurg-2019-015537 .

Time is of the essence for someone experiencing a stroke. Dr. Martin Radvany, Chief of Interventional Neuroradiology at UAMS, discusses stroke symptoms and treatment.

Today on Sojourner Truth: We shed light on a little-known and less-invasive medical procedure that has the potential to help tens of thousands of people. Our expert is Dr. George Teitelbaum, director of neurointerventional surgery for Providence, California. Before becoming a medical doctor, he did his undergraduate medical degree in biochemistry at UCLA. He received his medical degree from UC San Diego. He's taught at Georgetown University and USC, among others. He served as Director of Interventional Neuroradiology at Children's Hospital for more than two decades. He has a passion for ensuring that the general public are informed about their options to more radical medical interventions.

Today on Sojourner Truth: We shed light on a little-known and less-invasive medical procedure that has the potential to help tens of thousands of people. Our expert is Dr. George Teitelbaum, director of neurointerventional surgery for Providence, California. Before becoming a medical doctor, he did his undergraduate medical degree in biochemistry at UCLA. He received his medical degree from UC San Diego. He's taught at Georgetown University and USC, among others. He served as Director of Interventional Neuroradiology at Children's Hospital for more than two decades. He has a passion for ensuring that the general public are informed about their options to more radical medical interventions.

Today on Sojourner Truth: We shed light on a little-known and less-invasive medical procedure that has the potential to help tens of thousands of people. Our expert is Dr. George Teitelbaum, director of neurointerventional surgery for Providence, California. Before becoming a medical doctor, he did his undergraduate medical degree in biochemistry at UCLA. He received his medical degree from UC San Diego. He's taught at Georgetown University and USC, among others. He served as Director of Interventional Neuroradiology at Children's Hospital for more than two decades. He has a passion for ensuring that the general public are informed about their options to more radical medical interventions.

Dr. Ted Achacoso attained a college degree in biology at the age of 18 and a doctor of medicine at the age of 22. He is the founding pioneer of the clinical practice of Health Optimization Medicine and Practice (HOMe/HOPe), which is the detection and correction of imbalances at the level of the metabolome. He was mentored by Thierry Hertoghe, the founding pioneer of Anti-Aging Medicine and Nutritional Medicine (Dr. Ted is double board-certified, Paris). He was mentored by William S. Yamamoto, the founding pioneer of Medical Informatics and an Artificial Intelligence researcher (Washington, DC). He was also mentored by D. Wayne Silby, the founding pioneer of Socially Responsible Investing and Finance (Washington, DC) and by three Philippine pioneers in Interventional Neuroradiology, in Neurology, and in Pharmacology/Toxicology. His representative body of work includes , journal articles, US patents, software, grants, and recorded interviews, webcasts, podcasts, and speaking engagements in the areas of: (1) artificial ethology, computational neuroethology, biomathematical modeling of nervous systems, and computability of consciousness, (2) medical informatics, medical decision-making, connectionist systems, and expert systems, (3) computer-assisted imaging, edge detection algorithms, and telehealth, (4) virtual group dynamics, communication, and collaboration methods (He created the first wireless groupware), (5) parallel, cluster, cloud, and distributed emergent computing, (6) predictive complex adaptive system modeling of financial time series, and (7) health optimization medicine including metabolomics, epigenetics, bioenergetics, gut microbiota, exposomics, chronobiology, and evolutionary medicine. He is based in Washington, DC, maintains a tricontinental HOMe practice (North America, Europe, Asia), and performs HOMe/HOPe lecturing and mentoring to doctors and practitioners. Dr. Ted provides international corporate consulting activities involving nutritional supplement formulation and the establishment of metabolomics, mitochondria, and microbiota laboratories. He strongly suspects that this world is an illusion projected as a hologram by the human biocrystal, and pushes to create deliberately sustainable, happy dreams instead of nightmares. Dr. Achacoso has trained, researched, and worked in many different fields: 1) Interventional neuroradiology and pharmacology in Manila; 2) Medical informatics and artificial intelligence in Washington, DC; 3) Scientific advisor to local venture and global institutional investment funds in Bethesda, MD; 4) As Founder and Chief Technology Officer of a group communication and collaboration software company in Rosslyn, VA (He created the first wireless mobile groupware); 5) As a quant trader for an incubator hedge fund in Rehoboth Beach, DE; 6) In Anti-Aging Medicine and Nutritional Medicine in Paris, Brussels, Monte Carlo. His representative body of work includes a book containing the first-ever neural circuitry database (or the first-ever “connectome”) for an organism (C. elegans), journal articles, US patents, software, grants, and recorded interviews, webcasts, and speaking engagements in the areas of: 1) Artificial ethology, computational neuroethology, biomathematical modeling of nervous systems, and computability of consciousness; 2) Medical informatics, medical decision-making, connectionist systems, and expert systems; 3) Computer assisted imaging, edge detection algorithms, and tele-health; 4) Virtual group dynamics, communication and collaboration methods including the first wireless groupware systems; 5) Parallel, cluster, cloud, and distributed emergent computing; 6) Predictive complex adaptive system modeling of financial time series. **Here are a few of my upcoming public appearances: Paleo FX: Austin, TX - 24-28 April Community Talk on Stem Cell Procedure: Charleston, SC - 29 May  Swiss Retreat and Liver Detox: 23 June - 7 July Click to see more details about these and other upcoming events! During our discussion, you'll discover: -The homemade nootropic Dr. Ted took before the interview with Ben...8:30 Blue Cannatine Smart Troche Trokie: a lozenge inserted between the gums and teeth (limit exposure to saliva) Venture capitalist hated it, but then wanted to invest in it because of its efficacy 1 mg nicotine, 5 mg CBD -Whether or not Dr. Ted is really the smartest physician alive...11:35 He's pretty darn close (1 in a billion) -What is Health Optimization Medicine (HOMe) and Health Optimization Practice (HOPe)...12:45 HOMe is intended for physicians; HOPe is intended for practitioners The goal is for there to be more practitioners than physicians Dr. Ted was an interventional neuroradiologist (spoke brains for a living) Retrained in Europe in nutritional medicine in 2009; fields such as epigenetics, microbiota, etc. were becoming popular in the U.S. Metabalomics: Studying the metabolites produced during different chemical processes in the body Technology allows treating actual fundamental cells, versus symptoms at the organ level HOMe represents a more sophisticated "dashboard" to examine the body Our metabolites' "golden years" are between the ages of 21-30 Separate test for hormones (ideally blood) Why you can't treat/adjust just hormones They're all in a network Causes imbalance, brain receives and gives improper signals Network perspective vs. artificial intelligence -Dr. Ted's book about artificial intelligence and "connectomes"...27:55 He was made to choose between studying the computability of consciousness and beauty Was banned by the powers that be at M.I.T. (later apologized) Now referred to as "Deep learning" (marketing is king) We're too DNA centric -The 7 "pillars" of Dr. Ted's practice...35:45 Clinical and therapeutic metabalomics: detection and correction Epigenetics: "Genes are not your destiny" Bioenergetics (mitochondria): Symbiotic relationship with our environment Ion Profile with 40 Amino Acids by Genova Diagnostics Microbiota (gut immune system) 78% of your bacteria are in your gut They teach your immune system what's foreign, what's not People born via c-section are more prone to allergies, immune diseases Some c-sections, gauze is dipped in vagina, then rubbed on the head after birth Exposomics: The sum total of your exposure to your own lifestyle and environment (including in utero) Shows how your environment interacts with your genome to produce phenome (not phenotype) Detox protocols: Targeted supplementation Gut cleanup Phototoxicity (blue light isn't all bad) Chronobiology Evolutionary medicine -The "Rolls Royce" for hacking jet lag and tips for optimizing circadian biology...59:50 Hormone balancing Melatonin Growth hormone (injected) Thyroid (level rises in the morning) Cortisol tablets Gut enzymes Thorne Biogest + SEED Probiotics One "anchor" meal that is constant between time zones Erythropoietin Sleep hygiene: "Your day begins at the time you fall asleep" Treat your sleep as the first item on your list, not the last thing you do in the day Oura ring for sleep tracking (deep sleep inducing peptide) -Dr. Ted's guidance on diet...1:12:20 "Eating window" vs. "fasting window" Complete everything in one day Snowball effect (eat first and feel good, then get to work) Remove sensitive foods right away Dr. Ted's personal diet: Micro-nutrient optimized, macro-nutrient targeted Make your fattiest meal your first meal; second meal high fiber and carbs; third meal have protein Dr. Ted's morning coffee: MCT oil or powder Powdered cellulose (for fiber) Collagen fiber -And much more! Episode Sponsors: -: My personal playground for new supplement formulations. Ben Greenfield Fitness listeners receive a 10% discount off your entire order when you use discount code: BGF10. -: Contains a host of anti-inflammatory, anti-obesity, and anti-allergy benefits. For this reason, I have decided to now make consumption of hydrogen-rich water an important part of my daily nutritional routine...and I highly recommend it! Enter code: BEN at checkout and get 30% off your order! -: I’ve been using Four Sigmatic products for awhile now and I’m impressed by the efficacies of their mushroom products. I use them. I like them. I support the mission! Receive 15% off your Four Sigmatic purchase when you use discount code: BENGREENFIELD -: Quality is our Gimmick isn’t just our slogan, it’s a commitment we honor with every stitch we sew. 100% money back guarantee. Get 10% off your order, PLUS free shipping on any order over $99 when you use discount code: BENG. Do you have questions, thoughts or feedback for Dr. Ted or me? Leave your comments below and one of us will reply!  

Nesse episódio do Gene Highlights, gravado durante o quarto módulo do European Course of Diagnostic and Interventional Neuroradiology, realizado em fevereiro de 2019, em São Paulo, o Dr. Antônio Maia entrevista o radiologista Dr. Luiz Celso Hygino da Cruz Junior, que fala sobre as complicações das arboviroses em pacientes adultos.

Nesse episódio do Gene Highlights, gravado durante o quarto módulo do European Course of Diagnostic and Interventional Neuroradiology, realizado em fevereiro de 2019, em São Paulo, o Dr. Antônio Rocha entrevista o Dr. Gustavo Novelino Simão, que fala sobre os avanços no conhecimento das Leucodistrofias.

Nesse episódio do Gene Highlights, gravado durante o quarto módulo do European Course of Diagnostic and Interventional Neuroradiology, realizado em fevereiro de 2019, em São Paulo, o Dr. Antônio Rocha entrevista o neurologista Dr. Orlando Barsottini, que fala do papel da Radiologia no diagnóstico das encefalites autoimunes. Abaixo, seguem os artigos de referência dessa entrevista: Encefalites autoimunes: uma revisão sobre diagnóstico e tratamento http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000100041&lng=en&tlng=en Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology https://www.ncbi.nlm.nih.gov/pubmed/29053777

Struck by Stroke! Stroke Technology for full recovery with R.H.Rosenwasser MD, Professor and Chairman Department of Neurological Surgery, Neurovascular Surgery,Interventional Neuroradiology, President/CEO:  Farber Institute for Neuroscience

M2 occlusions can present with serious neurological deficits, resulting in large infarcts and significant morbidity and mortality. The paper discussed in this podcast concludes that patients with M2 occlusions and higher baseline deficits (NIHSS score ≥9) may benefit from endovascular therapy, thus potentially expanding the category of acute ischemic strokes amenable to intervention. Listen to the conversation between the Editor-in-Chief of JNIS, Felipe de Albuquerque, and Ansaar Rai (Department of Interventional Neuroradiology, West Virginia University Hospital, USA), who is the co-author of “A population-based incidence of M2 strokes indicates potential expansion of large vessel occlusions amenable to endovascular therapy”. Read the Editor’s Choice paper of June 2018 on the JNIS website: jnis.bmj.com/content/10/6/510.

Dr Hal Rice obtained his Medical Degree at the University of Queensland in 1992 and then completed his Internship and Residency at the Royal Brisbane and Women's Hospital. Hal undertook specialist training in Diagnostic and Interventional Radiology at the Royal Brisbane and Women's Hospital before doing an Advanced Specialist Fellowship in Diagnostic and Interventional Neuroradiology at the world famous Mt Sinai Medical Center in New York City in 2001 and 2002. Dr Rice talks about the use of state of the art technology to provide minimally invasive endovascular treatment of patients with life threatening brain aneurysms and acute stroke. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)